Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Merus. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Merus's earnings available for a low price, and how does
this compare to other companies in the same industry?
Merus is not considered high growth as it is expected to be loss making for the next 1-3 years.
Merus's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Merus's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Ton Logtenberg, Ph.D. has been Principal Financial Officer of Merus N.V. since January 2019. Dr. Logtenberg serves as President, Chief Executive Officer and Director of Merus N.V. since June 2003. Dr. Logtenberg serves as President of the subsidiary, Merus US, Inc. Dr. Logtenberg co-founded Crucell N.V. and served as its Executive Vice President and Chief Scientific Officer from July 2000 to November 2003. served as its External Advisor and Member of Management Board. He Co-founded U-BiSys and served as its General Manager and Chief Scientific Officer. Dr. Logtenberg served at the U-BiSys Management Board in June 2000, in connection with the merger between IntroGene and U-BiSys. From 1994 to 1995 he served as a Visiting Scientist at Becton Dickinson Immunocytometry Systems. He is a Professor of immuno-biotechnology at the University of Utrecht since 1996. Dr. Logtenberg is a part-time Professor and Staff Member of the Department of Immunology at the University Medical Center Utrecht. From 1989 to 1995 he was a Senior Researcher on a fellowship from the Royal Dutch Academy of Arts and Sciences. He has been an Executive Director of Merus B.V. since June 5, 2017. Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the board of directors of Utrecht Science Park since November 2014. From 1987 to 1989, Dr. Logtenberg was a post-doctoral fellow at the Howard Hughes Institute, Department of Biochemistry at Columbia University in New York. Dr. Logtenberg has a Masters in Biology and a Ph.D. from the University of Utrecht.
Ton's compensation has increased whilst company is loss making.
Ton's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Merus management team is about average.
Co-Founder and Scientific Advisor
Vice President of Investor Relations & Corporate Communications
John de Kruif
CTO & Senior VP
Chief Scientific Officer & Executive VP
CDO & Senior VP
Chief Business Officer
Chief Medical Officer & Executive VP
Executive Director of IP & Secretary
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Merus board of directors is less than 3 years, this suggests a new board.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.